Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of Angiotensin Receptor Blockers (ARB) versus Other Antihypertensive Medication on Blood Pressure in Patients on Dialysis: A Meta-Analysis

K. Devi D S, JJF. Mary, R. Mohan, D. Gavlasova, G. Kalaiselvan, E. Kathiravan, JA. Foppiani, V. Saravanan, A. Devi M, SJ. Lin

. 2024 ; 34 (5) : 431-441. [pub] 20240708

Status neindexováno Jazyk angličtina Země Indie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002484

INTRODUCTION: Hypertension is an important factor driving mortality among dialysis patients. Angiotensin-II receptor blocker (ARB) has been effective similarly to angiotensin-converting enzymes (ACEs) but with a low incidence of side effects. METHODOLOGY: The meta-analysis included all published studies that investigated the effect of ARB on the hypertension in adult dialysis patients (≥18 years). Data extraction was guided by a predetermined checklist. Data sources of the retrieved studies were PubMed, MEDLINE, ScienceDirect, SCOPUS, Cochrane, Web of knowledge, and Google Scholar were systematically searched until February 2023. Using the RevMan 5 software, the mean difference for systolic and diastolic BP (SBP and DBP) and the risk ratio (RR) of the adverse events (AEs) were pooled from the selected studies. The random-effects model was used to compare the difference in the pre-and post-dialysis of the SBP and DBP. Data analyses were performed from December 2022 to February 2023. The primary outcome was the reduction in SBP and DBP in dialysis hypertensive patients who were on anti-hypertensive agents, and the secondary outcome was assessment of AE associated with the drug after dialysis (PROSPERO Registration: CRD42022355369). RESULTS: The initial search yielded 1,679 records, of which 84 studies underwent full-text evaluation, which identified 13 studies and 1,462 patients. The pooled standard MD for losartan with other anti-hypertensive agents, where the pre-dialysis SBP was 0.17 (95% confidence interval [CI]: -0.21-0.55) and the post-dialysis was 0.35 (95% CI: -0.17-1.02); yet, both are statistically non-significant, implies that there was no difference between Losartan and ARB drugs regarding the effect on the SBP. Diastolic BP for predialysis was -0.01 (95% CI: -0.65-0.63) and post-dialysis was 0.03 (95% CI: -0.24-0.30) and statistically non-significant. AEs by the ARB agents were lower compared to other anti-antihypertensive agents (relative risk [RR]: 1.01; 95% CI: 0.59-1.75) and statistically non-significant. CONCLUSION: This systematic review and meta-analysis of RCT demonstrated that ARB and other anti-hypertensive medications had similar impacts on the treatment of hypertension.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002484
003      
CZ-PrNML
005      
20250123101919.0
007      
ta
008      
250117s2024 ii f 000 0|eng||
009      
AR
024    7_
$a 10.25259/ijn_365_23 $2 doi
035    __
$a (PubMed)39372639
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ii
100    1_
$a Devi D S, Karthika $u Department of Community Medicine, Sri Manakula Vinayagar Medical College and Hospital, Puducherry, India
245    10
$a Impact of Angiotensin Receptor Blockers (ARB) versus Other Antihypertensive Medication on Blood Pressure in Patients on Dialysis: A Meta-Analysis / $c K. Devi D S, JJF. Mary, R. Mohan, D. Gavlasova, G. Kalaiselvan, E. Kathiravan, JA. Foppiani, V. Saravanan, A. Devi M, SJ. Lin
520    9_
$a INTRODUCTION: Hypertension is an important factor driving mortality among dialysis patients. Angiotensin-II receptor blocker (ARB) has been effective similarly to angiotensin-converting enzymes (ACEs) but with a low incidence of side effects. METHODOLOGY: The meta-analysis included all published studies that investigated the effect of ARB on the hypertension in adult dialysis patients (≥18 years). Data extraction was guided by a predetermined checklist. Data sources of the retrieved studies were PubMed, MEDLINE, ScienceDirect, SCOPUS, Cochrane, Web of knowledge, and Google Scholar were systematically searched until February 2023. Using the RevMan 5 software, the mean difference for systolic and diastolic BP (SBP and DBP) and the risk ratio (RR) of the adverse events (AEs) were pooled from the selected studies. The random-effects model was used to compare the difference in the pre-and post-dialysis of the SBP and DBP. Data analyses were performed from December 2022 to February 2023. The primary outcome was the reduction in SBP and DBP in dialysis hypertensive patients who were on anti-hypertensive agents, and the secondary outcome was assessment of AE associated with the drug after dialysis (PROSPERO Registration: CRD42022355369). RESULTS: The initial search yielded 1,679 records, of which 84 studies underwent full-text evaluation, which identified 13 studies and 1,462 patients. The pooled standard MD for losartan with other anti-hypertensive agents, where the pre-dialysis SBP was 0.17 (95% confidence interval [CI]: -0.21-0.55) and the post-dialysis was 0.35 (95% CI: -0.17-1.02); yet, both are statistically non-significant, implies that there was no difference between Losartan and ARB drugs regarding the effect on the SBP. Diastolic BP for predialysis was -0.01 (95% CI: -0.65-0.63) and post-dialysis was 0.03 (95% CI: -0.24-0.30) and statistically non-significant. AEs by the ARB agents were lower compared to other anti-antihypertensive agents (relative risk [RR]: 1.01; 95% CI: 0.59-1.75) and statistically non-significant. CONCLUSION: This systematic review and meta-analysis of RCT demonstrated that ARB and other anti-hypertensive medications had similar impacts on the treatment of hypertension.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Mary, J Jenifer Florence $u Department of Community Medicine, Mahatma Gandhi Medical College and Research Institute, SBV (Deemed to be University), Puducherry, India
700    1_
$a Mohan, Reenaa $u Department of Community Medicine, Sri Manakula Vinayagar Medical College and Hospital, Puducherry, India
700    1_
$a Gavlasova, Dominika $u IKEM, Cardiology Resident, Institute of Clinical and Experimental Medicine, Charles University, Prague, Czechia
700    1_
$a Kalaiselvan, G $u Department of Community Medicine, AIIMS, Mangalgiri, Andhra Pradesh, India
700    1_
$a Kathiravan, E $u Department of General Medicine, Indira Gandhi Medical College and Research Institute, Puducherry, India
700    1_
$a Foppiani, Jose A $u BIDMC, Research Fellow, Division of Plastic Surgery, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, Massachusetts, US
700    1_
$a Saravanan, V $u Department of Community Medicine, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Melmaruvathur, Tamil Nadu, India
700    1_
$a Devi M, Archana $u Sri Lalithambigai Medical College and Hospital, Adayalampattu, Maduravoyal, Chennai, Tamil Nadu, India
700    1_
$a Lin, Samuel J $u BIDMC, Division of Plastic Surgery, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, Massachusetts, US
773    0_
$w MED00165522 $t Indian journal of nephrology $x 0971-4065 $g Roč. 34, č. 5 (2024), s. 431-441
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39372639 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250117 $b ABA008
991    __
$a 20250123101913 $b ABA008
999    __
$a ok $b bmc $g 2254601 $s 1238487
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 34 $c 5 $d 431-441 $e 20240708 $i 0971-4065 $m Indian journal of nephrology $n Indian J Nephrol $x MED00165522
LZP    __
$a Pubmed-20250117

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace